Muhammad Haq, MD
Endocrinology, Diabetes & Metabolism · Santa Barbara, CANPI 1710126388
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Abbott at 24.8% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 53 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$272
- Novartis$98
- Novo Nordisk$82
- Dexcom, Inc.$74
- AbbVie$65
- Sequel Med Tech, LLC$59
- plus $448 from 14 others
What the payments were for
- Food & beverage$1,08299%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $272 |
| Novartis | 3 | $98 |
| Novo Nordisk | 4 | $82 |
| Dexcom, Inc. | 4 | $74 |
| AbbVie | 3 | $65 |
| Sequel Med Tech, LLC | 3 | $59 |
| Amgen | 4 | $57 |
| Mannkind Corporation | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Medtronic | 2 | $47 |
| Tandem Diabetes Care, Inc. | 2 | $44 |
| AstraZeneca | 2 | $38 |
| Johnson & Johnson | 2 | $31 |
| Antares Pharma, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $23 |
| BD | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Insulet Corporation | 1 | $14 |
| Cequr Corporation | 1 | $11 |
How this compares
$1,096 in reported general payments places this provider in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 395 | $517,456 |
| TrulicityDulaglutide | 153 | $211,539 |
| MounjaroTirzepatide | 165 | $209,145 |
| FarxigaDapagliflozin Propanediol | 122 | $144,873 |
| Tresiba Flextouch U-100Insulin Degludec | 124 | $84,845 |
| JardianceEmpagliflozin | 81 | $79,069 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 48 | $73,713 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $59,565 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 67 | $59,090 |
| Xigduo XrDapaglifloz Propaned/Metformin | 57 | $52,471 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $34,434 |
| SynjardyEmpagliflozin/Metformin Hcl | 28 | $29,477 |
| JanuviaSitagliptin Phosphate | 17 | $26,280 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $25,387 |
| TradjentaLinagliptin | 36 | $23,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $82 | $517,456395 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $23 | $420,684318 claims |
| AstraZenecaFarxiga | $38 | $144,873122 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $52 | $59,09067 claims |
| MerckJanuvia | $16 | $26,28017 claims |
| AbbVieSynthroid | $65 | $17,823229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Santa Barbara
- Daniel BergerSanta Barbara$541K
- Tricia Westhoff-PankratzSanta Barbara$69K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.